Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Human duct cells contribute to β cell compensation in insulin resistance
Ercument Dirice, … , Jiang Hu, Rohit N. Kulkarni
Ercument Dirice, … , Jiang Hu, Rohit N. Kulkarni
Published April 18, 2019
Citation Information: JCI Insight. 2019;4(8):e99576. https://doi.org/10.1172/jci.insight.99576.
View: Text | PDF
Research Article Cell biology Endocrinology

Human duct cells contribute to β cell compensation in insulin resistance

  • Text
  • PDF
Abstract

The identification of new sources of β cells is an important endeavor with therapeutic implications for diabetes. Insulin resistance, in physiological states such as pregnancy or in pathological states such as type 2 diabetes (T2D), is characterized by a compensatory increase in β cell mass. To explore the existence of a dynamic β cell reserve, we superimposed pregnancy on the liver-specific insulin receptor–KO (LIRKO) model of insulin resistance that already exhibits β cell hyperplasia and used lineage tracing to track the source of new β cells. Although both control and LIRKO mice displayed increased β cell mass in response to the relative insulin resistance of pregnancy, the further increase in mass in the latter supported a dynamic source that could be traced to pancreatic ducts. Two observations support the translational significance of these findings. First, NOD/SCID-γ LIRKO mice that became pregnant following cotransplantation of human islets and human ducts under the kidney capsule showed enhanced β cell proliferation and an increase in ductal cells positive for transcription factors expressed during β cell development. Second, we identified duct cells positive for immature β cell markers in pancreas sections from pregnant humans and in individuals with T2D. Taken together, during increased insulin demand, ductal cells contribute to the compensatory β cell pool by differentiation/neogenesis.

Authors

Ercument Dirice, Dario F. De Jesus, Sevim Kahraman, Giorgio Basile, Raymond W.S. Ng, Abdelfattah El Ouaamari, Adrian Kee Keong Teo, Shweta Bhatt, Jiang Hu, Rohit N. Kulkarni

×

Figure 2

Insulin+ ductal cells and small islet clusters localized close to ducts are increased in LIRKO mice during pregnancy.

Options: View larger image (or click on image) Download as PowerPoint
Insulin+ ductal cells and small islet clusters localized close to ducts ...
(A) Representative immunofluorescence images obtained from control and LIRKO mice before, during, and after pregnancy and stained for insulin (shown in blue), glucagon (shown in red) and ductal marker DBA (shown in green). Insets point to DBA and insulin+ cells. (B) Quantification of DBA and insulin double-positive cells in pregnant and nonpregnant control and LIRKO mice (n = 3–5 mice per group, 2-tailed Student’s t test). (C) Representative immunofluorescence images showing small islet clusters positive for insulin (blue) or glucagon (red) and DBA (green). Insets point to clusters localized to ductal structure. (D) Quantification of the distance of scattered islet clusters (fewer than 10 islet cells) from the ducts. Groups are shown as percentage of total scattered islets that were counted (n = 3 pancreas sections analyzed per group for each time point, 2-tailed Student’s t test). Scale bars: 10 μm (A), 20 μm (C). #Control versus control, *control versus LIRKO, and §LIRKO versus LIRKO. Data are expressed as mean ± SEM. #P, §P, and *P < 0.05; **P < 0.01.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts